A client's guide to BPC-157 and TB-500 — what they are, what to ask your clinician, and how care actually works here.

Peptides have spent the last decade in the gray zone — confusing labels, anecdotal forums, and clinicians who'd rather not have the conversation. We think that's overdue for a rewrite.
BPC-157 and TB-500 aren't miracle compounds, and we won't talk about them like they are. They aren't a substitute for the boring, slow work — sleep, load management, eating enough protein. The most honest framing we can give you: they're one tool a clinician might reach for alongside that work, never instead of it.
This guide is what we walk through with clients in their first follow-up visit. Read it before the visit so the visit goes faster. Read it after the visit when you want to remember what was said and what to ask next time.
If anything in here contradicts what your clinician told you, follow your clinician. They've seen your bloodwork. We haven't.

BPC-157 — short for Body Protection Compound, fifteen amino acids long — was first studied as a fragment related to a protein found in the digestive tract. The form a pharmacy dispenses is that same short fragment, compounded and shipped to you under a nitrogen seal to keep it stable.
What it is, in one sentence: a peptide that's been studied for its role in tissue repair. We're deliberately not going to hand you a list of mechanisms and outcomes here — the honest picture is that the human evidence is still thin, and what matters for you is the conversation with your clinician, not a paragraph from us.
In our clinic, BPC-157 usually enters the conversation alongside something else — a return to training after an injury, a flare of an old gut issue, a recovery a client wants to support rather than just wait out. It's a complement to a plan, not the plan.
Before anyone starts, expect questions about your full history — pregnancy, anything your other doctors are managing, any medication that changes the picture. These aren't boxes to tick; they're the reason this runs through a clinician and not a shelf. If a screen turns up a reason to wait, we wait.
TB-500 is a synthetic fragment of thymosin beta-4, a protein the body draws on during wound healing. Where BPC-157 tends to come up for connective-tissue questions, TB-500 is studied across a broader range — which is exactly why your clinician decides whether either, both, or neither fits what you're dealing with.
The two come up together often enough that we get the question a lot: do you take them at the same time? Sometimes. The rough shape of the thinking — and this is your clinician's call, not ours — is that a connective-tissue complaint (a cranky tendon, an old gut issue) may not need a second peptide, while a more diffuse muscle-or-skin issue sometimes does. We're giving you the shape of the conversation, not a protocol to self-administer.
If your clinician does pair them, expect a defined block of weeks with a built-in re-evaluation — not an open-ended run. The doses, the cadence, and when to step down all come from your visit and live on your protocol card. Our job is to make sure the right vials and supplies arrive on the right week.
There's animal data, some early human data, and a lot of anecdotal forum data. The long-term safety picture in healthy adults isn't as settled as it is for older, widely approved medications, and we'd rather say that plainly than oversell. Your clinician weighs that against your situation — that's the whole reason this runs through a visit instead of a checkout cart.
The first week is the most common drop-off point. Clients expect to feel something immediately; the truth is more boring.
Most people feel nothing at all in the first few days. By the end of the first week, some clients notice that the injury they're treating has faded to "background noise" instead of "the thing they think about every time they move." That's the kind of signal we ask you to watch for.
If any of the second list happens, message the care team. The reply usually goes out the same day; don't wait for your scheduled follow-up.
We don't keep clients on continuous peptide protocols. The default is a defined cycle your clinician sets — a block of weeks on, then a planned break — with a re-evaluation before each new cycle.
The reasoning is partly biological and partly clinical: we want a clear off-cycle to see what actually carried over. Clients who feel best a few weeks in don't always feel better many months into an open-ended run, and the break is how we tell the difference.
A refill ships ten days before you're scheduled to run out. The week before, you'll get an email — same one your transactional receipts come from, same brand. You can skip, pause, change the dose, or come off entirely. None of those decisions require a phone call.
When the cycle ends, you stop. There's no taper. You finish the last vial, and the next refill doesn't ship unless you initiate a new cycle.
The most common client pattern we see is one cycle, then a long break, then a second cycle six to twelve months later when something new comes up. That's exactly how we'd run it on ourselves.
Use this guide as a working document. Bring questions to your next visit. The whole point is to make the visit do more for you, not less.
Written for Halcyon Wellness clients and their care team. Read it once, refer back when something changes, hand it to a friend who keeps asking what BPC-157 is.
Nothing here replaces a visit with your clinician — it sets the table for one.
Reviewed by the Halcyon Wellness clinical team in 2026.
Your clinician sets the dose and the schedule — we don't print a number here, because the right one depends on you. What we handle is the logistics: the syringes, the bacteriostatic water for reconstitution, and a protocol card that walks you through the first injection step by step. The injection itself is shallow, closer to an insulin pen than anything dramatic.